Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Research
Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Poster Session Abstracts

Abstract P6-05-05: The estrogen switch: Estrogen receptor alpha levels determine the proliferative response to estrogen

Lacey Haddon, Xiuying Hu, Hosna Jabbari and Judith Hugh
Lacey Haddon
1University of Alberta, Edmonton, AB, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiuying Hu
1University of Alberta, Edmonton, AB, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hosna Jabbari
2University of Victoria, Victoria, BC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Judith Hugh
1University of Alberta, Edmonton, AB, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1538-7445.SABCS19-P6-05-05 Published February 2020
  • Article
  • Info & Metrics
Loading
Abstracts: 2019 San Antonio Breast Cancer Symposium; December 10-14, 2019; San Antonio, Texas

Abstract

Background: The premise that estrogen promotes the growth of all estrogen receptor positive (ER) + breast cancers has led to anti-estrogen therapies as the standard of care for all ER+ tumors. Paradoxically, estrogen (E2) has demonstrated a therapeutic effect in the adjuvant, palliative and prevention of breast cancers in some women suggesting that there is a subset of ER+ breast cancers that may be growth-suppressed by E2. Our companion window-of-opportunity trial (abstract submitted) found E2 is growth suppressive for some post-menopausal women with high ER expressing tumors. We utilized an in vitro cell model to investigate whether differential growth responses to E2 could be due to transcriptional differences mediated by the level of the ER.

Method: We generated a stable MCF-7 transfectant (MCF7-ER) using a fluorescently labelled lentiviral plasmid with a doxycycline inducible ER and compared the response to E2 against an MCF-7 mock transfectant (MCF7-EM). We assessed changes in proliferation (S-phase fraction), gene regulation (RNA-Seq) and differential ER-DNA binding (chromatin immunoprecipitation (ChIP-Seq)). To determine if high levels of ER were causing changes in the underlying chromatin configuration, we compared our ChIP-Seq profiles against previously mapped DNA loop anchor regions obtained by chromatin interaction analysis by paired end-tag sequencing (ChIA-PET) on the MCF-7 parental cell line treated with E2 (Fullwood M et al. Nature 2009). Changes in DNA loop formation were assessed by fluorescence in situ hybridization (FISH) and chromatin conformation capture (3C).

Results: We confirmed previously published findings that increased ER expression in the presence of E2 leads to significant decreases in S-phase fraction (P = 0.003) with impaired transition at the G1/S and G2/M checkpoints. RNA-Seq studies defined 342 basally-upregulated genes in the MCF7-ER cells that became down-regulated after E2 treatment indicative of inverse regulation compared to the effect of E2 in the MCF7-EM mock transfectants. In E2-deprived conditions, there was an increased number of ER-DNA binding peaks in the high ER expressing cells (2,776 in MCF7-ER vs. 1,906 in MCF7-EM), suggesting unliganded ER may mediate basal gene transcription. Only 17 (5%) of the basally upregulated genes had ER binding at a proximal or distant anchor associated with previously mapped ER-DNA loops. This suggests that high ER expressing cells may develop a novel chromatin configuration that is distinct from those of parental MCF-7 cells. FISH analysis confirmed a significant increase in loop formation at the promoter region of the TFF1 gene in the MCF7-ER cells compared to MCF7-EM mock transfectants (P = 0) in the absence of E2. This DNA loop was maintained, though slightly decreased, after E2 treatment.

Conclusions: These results support a theoretical model where increased ER expression may enable a novel chromatin configuration which mediates a basal level of gene expression that switches to a growth-suppressive transcriptional response upon E2 treatment. Further elucidation of an anti-proliferative DNA configuration signature using MCF7-ER cells may generate a novel set of interactions that could serve as a strategy to predict a patient’s response to estrogens and endocrine therapies.

Citation Format: Lacey Haddon, Xiuying Hu, Hosna Jabbari, Judith Hugh. The estrogen switch: Estrogen receptor alpha levels determine the proliferative response to estrogen [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P6-05-05.

  • ©2020 American Association for Cancer Research.
Previous
Back to top
Cancer Research: 80 (4 Supplement)
February 2020
Volume 80, Issue 4 Supplement
  • Table of Contents

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract P6-05-05: The estrogen switch: Estrogen receptor alpha levels determine the proliferative response to estrogen
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Abstract P6-05-05: The estrogen switch: Estrogen receptor alpha levels determine the proliferative response to estrogen
Lacey Haddon, Xiuying Hu, Hosna Jabbari and Judith Hugh
Cancer Res February 15 2020 (80) (4 Supplement) P6-05-05; DOI: 10.1158/1538-7445.SABCS19-P6-05-05

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract P6-05-05: The estrogen switch: Estrogen receptor alpha levels determine the proliferative response to estrogen
Lacey Haddon, Xiuying Hu, Hosna Jabbari and Judith Hugh
Cancer Res February 15 2020 (80) (4 Supplement) P6-05-05; DOI: 10.1158/1538-7445.SABCS19-P6-05-05
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Poster Session Abstracts

  • Abstract PS17-48: Potential role of activated leukocyte cell adhesion molecule (ALCAM) in hepatocyte growth factor (HGF) signalling in vascular endothelial cells and implications in breast cancer
  • Abstract PS19-01: A sense-antisense RNA interaction drives metabolic reprogramming in metastatic breast cancer
  • Abstract PS18-21: Pulsed electric field exposure (PEFE) applied in breast cancer: A potential normothermic clinical cancer therapy
Show more Poster Session Abstracts

Hormonal Factors and Receptors

  • Abstract PS19-09: Alternative splicing events from progesterone exposure differ based on BRCA1 mutation status
  • Abstract P6-05-10: CUDC-101 enhances estrogen-mediated anticancer effects in ERβ+ TNBC
Show more Hormonal Factors and Receptors
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement